Concerns raised about potential cover-up of excess deaths through misleading tactics and vaccine safety issues.
-
Early concerns about rushing vaccines and potential safety risks highlighted by Professor Hotes. • 0:52
-
Warning about unique safety problems of coronavirus vaccines and immune enhancement phenomenon. • 2:03
-
Observation of immune pathology in animal models from coronavirus vaccines development. • 3:41
Investigation into excess mortality rates in Western countries raises concerns about potential cover-ups.
-
Excess mortality rates in highly vaccinated regions like the UK and US are a cause for concern. • 4:13
-
Bulgaria, with lower vaccination rates, shows lower excess mortality rates compared to highly vaccinated countries. • 5:09
-
Calls for investigations into excess deaths are being ignored in countries like Australia and the UK. • 7:01
-
Historical information from 2004 reveals scrutiny of emails from pharmaceutical company Merck. • 7:52
Uncovering potential cover-up of excess deaths due to vaccine risks and financial interests.
-
Vioxx, a non-steroidal anti-inflammatory drug, was pulled off the market by Merck due to safety concerns. • 8:22
-
Merck had to pay a settlement of 4.85 billion in 2007 for Vioxx-related issues. • 9:04
-
Concerns raised about excess deaths possibly linked to vaccines and the need for serious investigation. • 10:07
-
Autopsy and histological examination of tissue are crucial to identify causes of excess deaths. • 11:05
-
Financial interests may hinder a thorough investigation into excess deaths. • 11:35
-
Urgent push needed for a comprehensive investigation to ensure public safety. • 11:58
-
Warning against fast-tracking vaccines without proper evaluation. • 12:21
Analysis of vaccine communication plan, potential need for third immunization, and impact on virus transmission.
-
Communication plan for covid-19 vaccines and trusted spokesperson discussed. • 12:59
-
Emergency use authorization for vaccines explained and importance of getting vaccinated. • 13:22
-
Duration and effectiveness of two-dose vaccines in preventing viral transmission. • 13:37
-
Estimation of population vaccination thresholds to halt virus transmission. • 14:33
-
Importance of achieving high vaccination rates to interrupt virus transmission. • 14:47
-
Prediction of potential need for a third immunization with mRNA vaccines. • 14:54
-
Discussion on the necessity of a third immunization for complete protection. • 15:00
Challenges with defining full vaccination and concerns over potential future vaccine requirements.
-
Shifting goalposts in defining full vaccination to include booster doses. • 15:56
-
Potential need for regular booster shots, possibly twice yearly. • 16:44
-
Concerns over silence and lack of acknowledgment of potential issues. • 17:14
-
Warning about the consequences of ignoring discrepancies in vaccination data. • 17:21
-
Highlighting the importance of observing, anticipating, and addressing future challenges. • 17:43
-
Fear of desperate measures to cover up problems that should be addressed. • 17:50
-
Emphasis on the potential impact on lives if issues are not acknowledged and addressed. • 17:59